This is the authors' abstract. We don't add key points for this paper.
Almost 2 years into the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the number of cases of coronavirus disease 2019 (COVID-19), morbidity, and mortality are still increasing. In spite of the considerable progress in the development of the COVID-19 vaccines, adequate vaccination coverage has not been achieved even in the most developed countries, and a significant gap still exists among high-, middle-, and low-income countries. While vaccination plays a central role in controlling COVID-19's spread, some concerns remain surrounding the emergence of resistance of new variants against available vaccines and their waning of efficacy over time. The assessment of the neutralization efficiency of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine against different variants showed that neutralization against the omicron variant is lower compared with the previous variants of concern, even after the third dose of vaccine. Accordingly, evaluation of the effectiveness of 2 doses of BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (AstraZeneca) COVID-19 vaccines showed limited protection against symptomatic disease caused by the omicron variant. Notably, a booster dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) after primary immunization led to considerably improved protection against the omicron variant; however, the protection waned notably during the time.1-3 While it is clear that vaccination is the most effective tool for control of the pandemic, other important tools include anti–SARS-CoV-2 monoclonal antibodies (mAbs) and antiviral medications that are discussed. The omicron variant has a large number of mutations in the receptor-binding domain of the spike protein as the target for anti–SARS-CoV-2 mAbs. According to in vitro studies, the susceptibility of the omicron variant has markedly decreased to bamlanivimab plus etesevimab and casirivimab plus imdevimab, which led to the National Institutes of Health (NIH) recommending against their use for the omicron variant. Sotrovimab, however, retains activity against the omicron variant and remains recommended for high-risk outpatients with mild to moderate COVID-19 disease.4-7 Preclinical studies showed that bebtelovimab is also active against the omicron variant as well as the BA.2 omicron subvariant. Based on the recent US Food and Drug Administration (FDA) recommendation, there is no significant difference in clinical data between bebtelovimab alone compared with the combination of bebtelovimab with other monoclonal antibodies.4, 7 It has been shown that the combination of long-acting mAbs tixagevimab plus cilgavimab is active against the omicron variant; however, the product is authorized only in the United States for prophylaxis of COVID-19 in selected individuals. It is worthy to note that lack of drug accessibility in many countries, parenteral route of administration, required administration in health care facilities, and lack of clinical efficacy in most hospitalized patients are disadvantages of mAbs.4-7 The omicron variant was found to have mutations in the main protease and RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, which are the key targets for antiviral drugs.4 Consequently, concerns have been raised about the effectiveness of these antiviral drugs against the omicron variant of SARS-CoV-2. Preclinical studies supported susceptibilities of the omicron variant to remdesivir, molnupiravir, and nirmatrelvir (PF-07321332).8 Remdesivir is an RdRp inhibitor that has been approved by the FDA for the treatment of hospitalized patients with COVID-19. Also, early administration of remdesivir in the outpatient setting could lower disease progression in high-risk patients with COVID-19. The unstable concentrations in plasma, the need for intravenous administration, and the development of viral resistance to some variants are important disadvantages of remdesivir. Oral antiviral medications could be used easily following viral exposure before progression to advanced stages of the disease. Molnupiravir and Paxlovid (PF-07321332 and ritonavir) have received emergency use authorization (EUA) from the FDA for high-risk outpatients with mild to moderate COVID-19.4, 8, 9 Molnupiravir is another RdRp inhibitor with remarkable mutagenic effects on viral RNA, which seems to be effective against remdesivir-resistant SARS-CoV-2 viruses. The clinical application of molnupiravir has been mostly restricted due to the lack of sufficient evidence in the vaccinated population and the possible risk of genotoxicity, fetal harm, and bone and cartilage growth abnormalities. Nirmatrelvir (the active antiviral agent in Paxlovid) is an orally active 3C-like (3CL) protease inhibitor with a broad-spectrum antiviral activity against coronaviruses that is packaged with a commonly used pharmacokinetic boosting agent ritonavir to slow its metabolism. It is important to mention that nirmatrelvir and ritonavir are substrates of cytochrome P450 3A, raising the concern for potential serious drug-drug interactions. The concomitant medications of patients should be monitored carefully. In addition to the potential drug-drug interactions, the more complicated production process is another disadvantage of Paxlovid (Table 1).4 There are some promising medications with powerful antiviral effects and acceptable safety profiles in the preclinical studies that are currently in phase 3 clinical trials for the management of patients with COVID-19. AT-527, a double prodrug of a guanosine nucleotide, is an oral RdRp inhibitor with no detected cytotoxic effects in contrast to molnupiravir. Another orally administered antiviral medication, S-217622 (ensitrelvir), is a 3CL protease inhibitor. Unlike Paxlovid, S-217622 may have less significant drug-drug interactions.10 The omicron variant may not be the last SARS-CoV-2 variant of concern, and other variants with mutations in the different sites of the viral genome may be detected in the future. It is unknown whether the next dominant variant of the virus will be more infectious or more deadly compared with the omicron variant; however, there are potential concerns about the efficacy of vaccines, mAbs, and antiviral medications against the next variants of concern.11 Consequently, the introduction of medications with preserved activity against new variants should be considered along with the investigations on the available medications with well-known safety and efficacy profiles in the management of COVID-19. For example, the use of host-targeted antiviral medications, such as plitidepsin, could prevent future viral resistance. Plitidepsin is an inhibitor of eukaryotic translation elongation factor 1 alpha that is the main host factor for the replication of several viruses, such as SARS-CoV-2. Although preclinical studies showed highly effective antiviral activity of plitidepsin against SARS-CoV-2, its potential toxicities of host cell growth inhibition and apoptosis induction should be further considered.12 The angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 antagonist (TMPRSS2) proxalutamide is a second-generation androgen receptor antagonist with a good safety profile. It has been hypothesized that proxalutamide could have beneficial effects in the early stages of COVID-19 through decreasing viral entry to the host cells and decreasing inflammatory markers, such as tumor necrosis factor-α, which has been shown to play a central role in the pathogenesis of the disease. The clinical efficacy of proxalutamide should be evaluated in future studies.13 Additionally, the potential antiviral effects of other investigational medications, such as emetine, nitric oxide, apilimod dimesylate (LAM-002A), ONO-5334, MDL-28179, and brequinar against new variants of SARS-CoV-2 should not be ignored in future preclinical and clinical studies. Emetine could block the interaction of the viral RNA with eukaryotic translation initiation factor 4E and reduce the level of inflammatory biomarkers, such as interleukin-6. Nitric oxide is a selective pulmonary vasodilator with antiviral properties. Apilimod dimesylate is a PIKfyve inhibitor that is currently in clinical trials for the treatment of patients with COVID-19. Apilimod dimesylate inhibits host cell proteases and prevents the viral invasion. ONO-5334 and MDL-28179 are cysteine protease inhibitors that antagonize viral replication. Brequinar (DHODH) is an inhibitor of dihydroorotate dehydrogenase that blocks biosynthesis of viral RNA and has immunosuppressive activity.10, 12-15 In conclusion, given emerging of new variants of SARS-CoV-2, along with the development of effective vaccines against new variants, the future of COVID-19 medications will belong to the drugs that are resistant to the virus mutation with an appropriate safety profile. The focus of manufacturers should be on the development of drugs that are resistant to the virus mutations. Implementing further investigations is also a key to dynamically battling the virus mutations. The authors declare no conflicts of interest. There is no funding. For data availability, please contact the corresponding author.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Khiali et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: